In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.
The study revealed no new safety signals compared with previous reports.
The most common topics of tweets were early detection of disease, bereavement, and research.
Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE improved responses and survival outcomes.
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
The improvement in response did not translate to a survival benefit.
Adjuvant S-1 improved survival over surgery alone.
Both platinum-based chemotherapy regimens are standard of care for digestive system neuroendocrine carcinoma.
Adding docetaxel to cisplatin and fluorouracil improved overall survival.
The updated results are from a median survival follow-up of 18.5 months and 133 overall survival events.
About 59% of patients achieved a pathologic complete response.
Host-related biomarkers might predict toxicities associated with nivolumab treatment in patients with advanced gastric cancer
The addition of pembrolizumab to chemotherapy did not improve progression-free or overall survival.